From major journals, first or last author from the Institute for Cancer Research
Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS(2025) Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient Cell Death Dis, 16(1), 555 DOI 10.1038/s41419-025-07884-7, PubMed 40701968
Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L(2025) Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer Breast Cancer Res, 27(1), 131 DOI 10.1186/s13058-025-02082-x, PubMed 40660361
Juvkam IS, Zlygosteva O, Schreurs OJF, Edin NJ, Galtung HK, Malinen E, Søland TM(2025) Regional atrophy, cellular plasticity, and regenerative potential in irradiated murine salivary glands Acta Oncol, 64, 927-938 DOI 10.2340/1651-226X.2025.44012, PubMed 40697181
Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS(2025) Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient Cell Death Dis, 16(1), 555 DOI 10.1038/s41419-025-07884-7, PubMed 40701968
Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A(2025) Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models Med Oncol, 42(8), 362 DOI 10.1007/s12032-025-02925-9, PubMed 40694184
